500.02 Clinical Outcomes At 2 Years of The Absorb Bioresorbable Vascular Scaffold Versus The Xience Drug-eluting Metallic Stent In Patients Presenting With Acute Coronary Syndrome Versus Stable Coronary Disease - Aida Trial Sub-study.

Ruben Y.G. Tijssen,Rene J. van der Schaaf,Robin P. Kraak,Maarten A. Vink,Sjoerd H. Hofma,Karin Arkenbout,Auke P.J.D. Weevers,Laura S.M. Kerkmeijer,Patrick W. Serruys, Yoshinobu Onuma,Marcel A.M. Beijk,Karel T. Koch, Jan Baan,M Marije Vis,Jan J. Piek,Jan Gp. Tijssen,Jose Ps. Henriques,Robbert J. de Winter, Joanna J. Wykrzykowska

JACC-CARDIOVASCULAR INTERVENTIONS（2019）

引用 4|浏览122

暂无评分

摘要

Patients with acute coronary syndrome (ACS) might represent a specific subgroup, in which bioresorbable scaffold implantation in percutaneous coronary intervention (PCI) might lead to better outcomes when compared to conventional treatment with metallic drug-eluting stents. ACS patients (STE-ACS

查看译文

关键词

metallic stent,acute coronary syndrome,drug-eluting,sub-study

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要